目前的流感疫苗是通过在鸡蛋中接种或者细胞培养的方式获得,其生产过程烦琐、耗时。这意味着当流感暴发时,疫苗的充足供应会成为难题。根据信使RNA的序列具有很容易被改变以便与新的流感毒株发生配对的优点,其制造过程也相当简单、迅速,可作为一种有用的替代物。研究人员通过给小鼠、雪貂和猪接种信使RNA疫苗来测试其有效性,发现这种疫苗产生的免疫应答相似甚至优于那些市售疫苗。信使RNA疫苗还具有以下优势: The current flu vaccine is obtained by inoculation or cell culture in eggs, and its production process is cumbersome and time-consuming. This means that when the flu breaks out, adequate supplies of vaccines can become a problem. The sequence of messenger RNAs has the advantage of being easily adapted for pairing with new influenza strains and the manufacturing process is relatively simple and rapid and can be used as a useful alternative. The researchers tested the effectiveness of vaccination of mice, ferrets and pigs with the messenger RNA vaccine and found that the vaccines produced similar or better immunizations than the commercially available vaccines. The messenger RNA vaccine also has the following advantages: